Low dose oestrogen and osteoporosis prevention

Heikkinen, Jorma
March 2000
Journal of the British Menopause Society;2000 Supplement, Vol. 6, p12
Academic Journal
The article presents information on low dose oestrogen and its contribution to the prevention of osteoporosis. The low-dose continuous combined therapy of hormone replacement therapy is explored as it shows the potential to be better tolerated by patients. Studies show that lower doses of oestrogen exhibit effectiveness in early and late postmenopausal women.


Related Articles

  • Clinical effects of raloxifene hydrochloride in women. Khovidhunkit, Weerapan; Shoback, Dolores M. // Annals of Internal Medicine;03/02/99, Vol. 130 Issue 5, p431 

    Examines clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was approved for the prevention of osteoporosis in postmenopausal women. Findings showing beneficial effects of raloxifene in selected organs in postmenopausal women.

  • Effect of Lower Doses of Conjugated Equine Estrogens With and Without Medroxyprogesterone Acetate on Bone in Early Postmenopausal Women. Lindsay, Robert; Gallagher, J. Christopher; Kleerekoper, Michael; Pickar, James H. // JAMA: Journal of the American Medical Association;5/22/2002, Vol. 287 Issue 20, p2668 

    Context: Lower-than-commonly-prescribed doses of conjugated equine estrogens (CEEs) with medroxyprogesterone acetate (MPA) improve vasomotor symptoms and vaginal atrophy, provide acceptable bleeding and lipid profiles, and afford endometrial protection. This lower-dose therapy's protection...

  • Meno pause. Brotherston, Jenny; Ritchie, Sara // Pulse;Feb2016, p58 

    The article presents questions and answers related to menopause including the recommendation of oestrogen for women in their early 50s, the use of hormone replacement therapy for the treatment of osteoporosis and the use of a transdermal preparation for women with cardiovascular diseases.

  • Should new estrogen carry warning in labeling? Portyansky, Elena // Drug Topics;3/2/98, Vol. 142 Issue 5, p28 

    Reports on the effectiveness of the Evista (raloxifene) which is described as the first designer estrogen to emerge for the prevention of osteoporosis in postmenopausal women. Responsibilities of Samuel Epstein, medical doctor, chairman of the Cancer Prevention Coalition and professor of...

  • Managing menopausal symptoms. Foran, Terri // Australian Prescriber;Dec2010, Vol. 33 Issue 6, p171 

    Until the mid 1990s, hormone therapy was seen as not only a safe means of relieving troublesome menopausal symptoms but as a way of preserving youth and vitality. Adverse findings from a number of studies in the 1990s cast doubt on some of the earlier claims, but it was the publication of the...

  • When HT makes sense. JVTR // Prevention;Feb2005, Vol. 57 Issue 2, p48 

    Discusses hormone therapy and how starting therapy prior to menopause may benefit the heart. Description of the Kronos Early Estrogen Prevention Study; What the study will investigate.

  • Panel Session: Prevention/Treatment: The Risks and Benefits of Long-Term Estrogen Replacement Therapy. Barrett-Connor, Elizabeth L. // Public Health Reports;Sep/Oct89 Supplement, Vol. 104, p62 

    Estrogen replacement therapy (ERT) for postmenopausal women greatly reduces the risk of osteoporotic fractures, but carries an increased risk of endometrial cancer. This risk can be reduced by the addition of progestin, which does not interfere with the osteoporotic benefit of estrogen. Although...

  • Prescribing menopausal hormone therapy: an evidence-based approach. Sood, Richa; Faubion, Stephanie S.; Kuhle, Carol L.; Thielen, Jacqueline M.; Shuster, Lynne T. // International Journal of Women's Health;2014, Vol. 6, p47 

    The constantly changing landscape regarding menopausal hormone therapy (MHT) has been challenging for providers caring for menopausal women. After a decade of fear and uncertainty regarding MHT, reanalysis of the Women's Health Initiative data and the results of recent studies have provided some...

  • Current Status of Hormone Replacement Therapy in Post Menopausal Women. Gupta, Madhur; Kohli, Kamlesh // Current Drug Therapy;Jan2007, Vol. 2 Issue 1, p11 

    Assessment of the risks versus the benefits of hormone replacement therapy has become a challenging task for the physicians. Controversial issues have surrounded the status of hormone replacement therapy for postmenopausal women lately. Several randomized controlled trials present contradicting...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics